Resource Ultilisation and Cost Analysis of

Memantine in Patients with Moderate to

Severe Alzheimer‘s Disease

Wimo A., Winblad B., Stöffler A., Wirth Y., and Möbius H. J.

Pharmacoeconomics 2003, 21 (5): 327-340

No. of patients N = 252 (outpatients)

Diagnosis Probable Alzheimer’s disease

Design Double-blind, randomized, placebo-controlled, multicenter study

Age 50 years (mean 76)

Severity MMSE 3 – 14 (mean 7.9)GDS 5 – 6FAST 6a

Dose; duration 20 mg Memantine/day; 28 weeks

Pharmaco- Resource Utilisation in Dementia (RUD) economic analysis

Study Design

Wimo et al., Pharmacoeconomics 2003

Baseline Characteristics

No significant differences in demographics and

the severity of the disease between treatment

groups

Very high degree of mean caregiving time in this

moderate to severe AD population

Wimo et al., Pharmacoeconomics 2003

Memantine Treatment Reduces Rate of Institutionalizations

p-value analyzed by 2 test

TPP, N = 166 Patient residential status at week 28

Wimo et al., Pharmacoeconomics 2003

Memantine Placebo

Residential status N (%) N (%) p-value

Community 83 (92.2 %) 62 (81.6 %)

0.04

Institutional 7 (7.8 %) 14 (18.4%)

Memantine Treatment Reduces Monthly Caregiver Resource Utilization

* corrected for baseline characteristics (ANCOVA model)

TPP, N = 166 Mean time over 28-week study period

Wimo et al., Pharmacoeconomics 2003

Memantine Placebo Difference

(N = 90) (N = 76)

Caregiver time 413.46 455.64 52*(hours) [SD] [234.27] [232.70]

Work loss 9.81 14.05 4.24(hours) [SD] [29.60] [38.72]

Significant Reduction of Costs through Memantine Treatment

US

Do

llars

/ m

on

th

* p < 0.03, ** p < 0.01 versus placebo

Total caregiver costs Total societal costs

8400

8000

7600

7200

6800

6400

6000Memantine Memantine

*

**

Placebo Placebo

TPP, N = 166 Adjusted mean monthly costs

Wimo et al., Pharmacoeconomics 2003

Summary

* corrected for confounding effects

Caregiver time and institutionalization were the main

cost drivers

Average monthly caregiver costs were $ 824 lower in the

memantine group*

Average monthly societal costs were $ 1090 lower in the

memantine group*

Conclusion:

Memantine treatment may lead to significant cost

savings by reduction of resource utilization

Wimo et al., Pharmacoeconomics 2003